Discussion These 2 cases illustrate the potential role of ruxolitinib as salvage therapy for
refractory HLH exhibiting a rapid and durable clinical benefit. To date, one of the patients has …

Somatic mutations in spliceosome genes are found in ∼50% of patients with myelodysplastic
syndromes (MDS), a myeloid malignancy associated with low blood counts. Expression of …

Somatic mutations in the spliceosome gene U2AF1 are common in patients with myelodysplastic
syndromes. U2AF1 mutations that code for the most common amino acid substitutions …

Somatic mutations in the spliceosome gene U2AF1 are common in patients with myelodysplastic
syndromes. U2AF1 mutations that code for the most common amino acid substitutions …

… Fei DL, Zhen T, Durham B, Ferrarone J, Zhang T, Garrett L, et al. Impaired hematopoiesis
and leukemia development in mice with a conditional knock-in allele of a mutant splicing …

Heterozygous somatic mutations in the spliceosome gene U2AF1 occur in ∼11% of patients
with myelodysplastic syndromes (MDS), the most common adult myeloid malignancy. It is …

Somatic mutations in spliceosome genes are detectable in ∼50% of patients with myelodysplastic
syndromes (MDS). We hypothesize that cells harbouring spliceosome gene mutations …

Next generation sequencing (NGS) methods have allowed for unprecedented genomic
characterization of acute myeloid leukemia (AML) over the last several years. Further advances …

Background Involvement of the central nervous system (CNS) by acute leukemias (ALs) has
important implications for risk stratification and disease outcome. The clinical laboratory …

Mutations in spliceosome genes are detectable in ~50% of patients with myelodysplastic
syndromes (MDS), making this cellular pathway the most commonly mutated in MDS and …